In a significant overseas acquisition, Sun Pharmaceutical Industries, India’s largest pharmaceutical company, and US-based Organon & Co have announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion (around Rs 1.10 lakh crore). Organon, based in New Jersey and listed on the New York Stock Exchange, is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the US and Canada, in 2021. The acquisition is expected to fortify Sun Pharma’s position in the global pharma market, especially the US. The deal is especially significant given that it comes when the Donald Trump administration is progressively disincentivising foreign pharmaceutical manufacturers, especially makers of non-generics and those shopping in drugs from other manufacturing hubs.…